Machine signal
Active cluster sell — 3 distinct insiders, $34K, window ends Sep 3, 2026.
Figures computed from official regulatory filings — .
Analysttarget 5.9 USD (+125%) · consensus 4.08/5 · 8 buy · 3 hold · 2 sell
Ownershipinsiders 0.18% · institutions 79.32% · short 19.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Editas Medicine, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
37 buys218 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Ory Daniel Scott | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Neill Gilmore Neil | Sell | $15.6K | SEC |
| Burkly Linda | Sell | $2.2K | SEC |
| Parison Amy | Sell | $1.4K | SEC |
| Ellinor Patrick Thomas II | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parison Amy | Sell | $1.7K | SEC |
| Burkly Linda | Sell | $13.2K | SEC |
| Scadden David | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Levy Elliott M. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hopfield Jessicatrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Connaughton Bernadette | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hirsch Andrew | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burkly Linda | Sell | $2K | SEC |
| O'Neill Gilmore Neil | Sell | $41.5K | SEC |
| Parison Amy | Sell | $1.3K | SEC |
| Parison Amy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burkly Linda | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Neill Gilmore Neil | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Burkly Linda | Sell | $1.5K | SEC |
| Parison Amy | Sell | $957.5 | SEC |
| O'Neill Gilmore Neil | Sell | $10.9K | SEC |
| Burkly Linda | Sell | $1.5K | SEC |
| Parison Amy | Sell | $991.2 | SEC |
| O'Neill Gilmore Neil | Sell | $12K | SEC |
| Parison Amy | Sell | $1.2K | SEC |